Skip to content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Tuesday, December 9, 2025
World Today News
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Copyright 2021 - All Right Reserved
Home » Metabolic Diseases » Page 7
Tag:

Metabolic Diseases

Health

Academia Europaea’s guidelines for the visualization of clinical outcomes

by Dr. Michael Lee – Health Editor October 14, 2025
written by Dr. Michael Lee – Health Editor

Academia Europaea issues New Guidance on‍ Clinical Outcomes Visualization

BUDAPEST, HUNGARY – Academia Europaea has released ‌guidelines aimed at ​improving the clarity and accuracy of clinical outcomes visualization, a critical component of modern medical research and practice. ⁣The initiative, drawing on expertise from a diverse international panel, seeks ​to standardize ‍how data is presented, enhancing reproducibility and facilitating informed decision-making. ‌

The advancement of thes​ guidelines involved contributions from researchers across multiple disciplines and institutions, including​ the Department of Pharmacology⁢ and Pharmacotherapy at Albert Szent-Györgyi Medical School, ‌University of Szeged (Varro, OtherS); the HUN-REN-SZTE Research Group ​for Cardiovascular Pharmacology (Varro,⁢ Other’s); the‍ Institute of Pathology,⁣ Friedrich-Alexander University Erlangen-Nuremberg (Vieth, Michael);⁢ the ​Department of General Practice and Health Services Research, Heidelberg University (Wensing, Michel); the centre ⁤for ⁤Population Health, ⁤National University of Singapore (Wong,​ John E.⁢ L.); the Institute of Digestive ⁤Disease, CUHK-Shenzhen Research Institute (Yu,​ Jun);‌ the institute for Translational Medicine‍ and pharmacology, Icahn School ​of Medicine at Mount Sinai ​(Mone​ more); the Division of Infection and Immunity, ⁢University College London ‍(Zumla, Alimuddin); the Department of Biostatistics, university of Veterinary ‍Medicine Budapest‌ (Harnos, Andrea); the Department of Radiology, Semmelweis University ⁤(Teutsch, Brigitta); the School of Biomedical ​Sciences, University⁣ of Leeds (Kuppuswamy, annapoorna); the Department of Mathematics Education, Loughborough University (Morsa, Kinga); and the Department of Plant Anatomy, ELTE​ Eötvös Loránd ‍University (Solymosi, Catherine).

The guidelines address key⁣ areas such as appropriate chart selection, data labeling, and the avoidance of misleading visual representations. A core principle emphasizes ‌transparency in data presentation to ensure that visualizations accurately reflect the underlying ⁣clinical trial or observational study results. ⁢further details regarding the guidelines and their implementation ⁤are expected to‌ be published in a forthcoming report.

October 14, 2025 0 comments
0 FacebookTwitterPinterestEmail
Health

Ebola vaccine safe for mothers and infants

by Dr. Michael Lee – Health Editor October 14, 2025
written by Dr. Michael Lee – Health Editor

Ebola Vaccine Confirmed ‌Safe for Pregnant and ​breastfeeding Women,Infants,in landmark Trials

New‍ research confirms the safety and immunogenicity of an Ebola vaccine for mothers and their infants,offering a critical advancement in ⁢protecting vulnerable populations⁤ during outbreaks. Published in the ‌ New England Journal of​ Medicine ‍ in⁤ November 2024, and further supported by a 2025 study in Vaccine, the findings demonstrate ‍a robust immune response in both vaccinated mothers ‌and their babies, even⁢ those ‌exposed in utero or through breastfeeding. This breakthrough addresses a ⁤notable gap in Ebola preparedness, as previous vaccine trials largely excluded pregnant and breastfeeding women, leaving them and their newborns at heightened risk.

The ‍confirmation is notably vital given the ⁤devastating impact Ebola has on families and communities,⁣ and the increased ‌vulnerability of pregnant women and infants to the ⁣virus. Prior to these studies, ethical concerns and a lack of data prevented widespread vaccination of these ⁣groups ⁤during ⁤outbreaks.The new⁤ data,⁢ stemming​ from trials in areas ‍previously affected by Ebola, paves the way for ‌including them in future vaccination campaigns, perhaps saving countless lives. Researchers ⁣anticipate ⁣these findings will promptly influence public health strategies and‌ vaccine deployment ⁢protocols ⁤in regions at ⁤risk of Ebola.

The⁢ New England Journal of Medicine study (DOI: 10.1056/NEJMp2410045) involved analysis⁣ of data related‌ to the vaccine’s performance, revealing no safety signals in vaccinated mothers ‍or their infants​ (Nachega, JB, 2024). A subsequent study published in Vaccine in 2025 (DOI: 10.1016/j.vaccine.2024.126479) by Chaudhary, M. et al., further validated these findings, demonstrating a strong immune response in⁢ infants, even those born to mothers vaccinated during pregnancy. Both studies utilized data available through PubMed (39197097, 39488189) ‍and Google Scholar.

October 14, 2025 0 comments
0 FacebookTwitterPinterestEmail
Health

AI in Healthcare: Balancing Innovation with Human Oversight

by Dr. Michael Lee – Health Editor October 13, 2025
written by Dr. Michael Lee – Health Editor

AI in Healthcare: ⁤Experts Urge Human Oversight to Prevent Deskilling ‍and Ensure Patient Safety

London,UK – As artificial intelligence rapidly integrates into ‌healthcare,concerns are mounting over ⁤it’s potential impact on both patient trust and clinician ⁣skill. Experts are emphasizing the critical need for “human-in-the-loop” systems – maintaining human oversight – to ensure responsible and effective⁢ AI implementation, particularly in high-risk⁤ areas like clinical decision support.

Growing public anxieties focus on the use of large‍ language models⁢ (LLMs) as unlicensed therapy chatbots3,‍ with reports⁣ surfacing of AI-mediated​ delusions,⁣ suicidal ideation, and even instances of bromide poisoning.This⁤ raises questions about‍ building ​patient ​trust, especially when individuals may turn to chatbots instead of their doctors for medical advice2.

Recent research highlights the potential‍ for ⁤AI to inadvertently decrease human expertise. A study found that endoscopists who utilized ‌AI assistance for polyp detection⁢ experienced a decline in their detection rates after ‍just three ​months without the tool4, suggesting continuous AI exposure could lead to physician deskilling.

Though, experts believe these risks can be mitigated. Drawing ​parallels to aviation, where pilots regularly ⁢retrain on manual controls to ⁤avoid over-reliance on autopilot, they suggest periodic ​retraining for⁤ clinicians could counter algorithmic dependence.

The key, researchers emphasize, lies in understanding how ⁣ AI ⁣is ​integrated into clinical workflows.‍ Rigorous⁤ trials and real-world⁣ testing are needed‍ to​ identify potential‍ pitfalls and develop‍ a clear framework of‍ accountability for AI-related errors.

Ultimately, the future of medical ⁢AI hinges on a relational ⁢approach, treating clinicians as active partners rather than ‍passive users, and focusing on systems that leverage ⁢the‍ strengths of both humans ⁢and machines to overcome ‌their individual biases and limitations.


2 Nature, https://www.nature.com/articles/s41591-025-04033-7#ref-CR2
3 STAT, ⁤http://bit.ly/4305RLU (3 September 2025)
4 Budzyński, K. et al. Lancet⁣ Gastroenterol.⁢ hepatol.10, 896-903 ‌(2025).

October 13, 2025 0 comments
0 FacebookTwitterPinterestEmail
Health

Blood Gene Expression Reveals Sepsis and Critical Illness Mechanisms

by Dr. Michael Lee – Health Editor October 13, 2025
written by Dr. Michael Lee – Health Editor

“`html

Blood-Based Biomarkers Offer New Hope‍ for Precision Therapy in Sepsis⁢ and Critical Illness

Table of Contents

  • Blood-Based Biomarkers Offer New Hope‍ for Precision Therapy in Sepsis⁢ and Critical Illness
    • sepsis: A Persistent Global Health Challenge
    • Frequently Asked Questions about sepsis and Precision ‍Therapy

A breakthrough published​ online October 10, 2025, in nature medicine reveals that analyzing gene expression in‌ blood​ samples can identify crucial molecular and cellular responses in ⁤patients battling ⁣sepsis and other critical illnesses. this revelation ‌opens the door to developing targeted, mechanism-anchored therapies, ‍moving​ beyond the current ‘one-size-fits-all’ approach.

Did You Know? …

Pro Tip: Early identification of⁢ sepsis is critical.Knowing the signs and seeking immediate‌ medical attention ‌can substantially improve outcomes.

Three autonomous studies, ⁣detailed in the Nature Medicine report (doi:10.1038/s41591-025-04005-x), all converged on the power of blood-based gene expression data. Researchers ‌found distinct “host response signatures” – ‍patterns of gene activity ‍- that correlate with the severity of illness and⁤ predict patient outcomes. These signatures aren’t about the pathogen ‍causing the​ infection,but rather how ‍the body ‌ is responding to it.

“These findings ‍represent a significant step towards personalized medicine ‌in critical ⁤care,” notes a commentary accompanying ‌the publication.

Currently, sepsis treatment largely relies on broad-spectrum antibiotics and supportive care. ​While life-saving,⁤ these approaches⁤ can contribute ⁤to antibiotic resistance and don’t​ address the underlying biological mechanisms driving the illness.Understanding the host response allows clinicians⁣ to potentially tailor treatments to the individual patient’s immune⁢ profile.

The ⁣research highlights the potential for developing therapies that modulate ‍the immune system, reducing inflammation ⁢or boosting specific⁤ immune⁤ functions as needed. This precision approach ‌could minimize side effects and maximize treatment​ efficacy. The⁣ studies‍ examined a range of critical ⁣illnesses beyond sepsis, suggesting the host response signatures identified may have broader applicability.

As precision medicine advances,the ability to rapidly assess a patient’s molecular profile⁣ will become⁣ increasingly significant. These blood-based biomarkers⁤ offer a relatively non-invasive and ⁣scalable‌ way to ⁢achieve this.

What are your thoughts⁢ on the potential of precision medicine to revolutionize‍ critical care? ⁢ Do you ‌think widespread adoption of these biomarkers is feasible in the near future?

sepsis: A Persistent Global Health Challenge

Sepsis remains a⁢ leading cause of death worldwide, affecting millions each year. ‍The condition arises when the body’s response ​to an⁣ infection spirals out of control,‍ damaging its own tissues ‍and ⁣organs. Early⁣ diagnosis and intervention are crucial, but often delayed due to the non-specific⁤ symptoms. Research⁤ into the underlying ‌mechanisms of sepsis, like ⁣the‌ work published in Nature Medicine, is vital to improving patient outcomes and reducing⁢ the global⁢ burden of⁣ this devastating ‌illness.

Frequently Asked Questions about sepsis and Precision ‍Therapy

  • What is a host‌ response ‌signature in sepsis? It’s a unique pattern of gene activity in the ‍blood that reflects‍ how the body is reacting to an​ infection during sepsis.
  • How can precision therapy help with sepsis? Precision therapy ⁢aims ⁣to tailor treatments to an ⁣individual’s ⁢specific immune​ response, potentially improving effectiveness​ and reducing side effects.
  • Is this blood⁤ test widely‌ available now? While the research ⁤is ​promising,⁣ these ⁣tests are not yet standard clinical practice. Further ⁤validation and implementation⁢ are⁤ needed.
  • What are the ‍current treatments for sepsis? Current treatments primarily involve antibiotics, fluids, and supportive care to stabilize ‍the patient.
  • Can these biomarkers‌ help predict sepsis before symptoms appear? The ⁤research⁢ focuses on identifying signatures ⁣*during* illness, but⁤ future‌ studies may ‍explore predictive⁣ capabilities.
  • What⁢ role ‍dose inflammation play ​in ​sepsis? ‌ ⁤ Uncontrolled inflammation is a key driver of tissue ⁤damage in sepsis,and modulating the inflammatory response is a‌ target for precision therapies.

We’re thrilled to share this exciting ‍progress​ in⁢ sepsis research with you!⁤ If you found this article informative, please⁣ consider sharing it ⁢with your network, leaving ‌a comment with

October 13, 2025 0 comments
0 FacebookTwitterPinterestEmail
Health

Developing cell therapies for lupus

by Dr. Michael Lee – Health Editor October 11, 2025
written by Dr. Michael Lee – Health Editor

“`html

CAR T-Cell‍ Therapy Shows Promise in early Lupus​ Trials

Table of Contents

  • CAR T-Cell‍ Therapy Shows Promise in early Lupus​ Trials
    • The ​Landscape of Lupus⁢ Treatment
    • Frequently Asked Questions‌ about⁢ CAR T-Cell‍ Therapy​ for ‌Lupus

In a significant ⁢step forward for autoimmune disease treatment,early clinical trials are demonstrating encouraging results with‌ CAR T-cell therapy in patients battling systemic‌ lupus erythematosus ‍(SLE), commonly⁤ known as ‍lupus.published online October 10, 2025, in Nature Medicine, two phase 1 studies suggest this innovative approach ⁢could offer a new avenue for managing ⁤the ⁣debilitating effects of this chronic autoimmune condition. The research, detailed in doi:10.1038/s41591-025-03987-y,highlights‌ the potential of reprogramming a patient’s own immune cells to target‌ and suppress‍ the autoimmune response characteristic of lupus.

Lupus, affecting an estimated five million people worldwide, causes the immune ⁢system⁣ to attack​ its own tissues and organs. Current treatments often rely on broad immunosuppression, leaving patients vulnerable ​to infections and othre ⁣side effects.⁤ CAR T-cell therapy, initially developed for⁤ cancer‍ treatment, offers a more targeted approach.⁢ It⁢ involves extracting‍ T ​cells from a patient, genetically modifying them to express a chimeric antigen receptor (CAR) that recognizes a specific target ‍on immune cells contributing to the autoimmune process, and then reinfusing them back into the patient.

The phase 1 trials focused on safety‌ and initial efficacy.⁢ While the results are preliminary, they‌ indicate that CAR‌ T-cell therapy can ⁣induce remission in some patients with severe lupus. However, researchers ​caution that further investigation is crucial. As ‌noted in ​the ‌ nature Medicine ​publication, ‍key challenges remain regarding the design of future trials, particularly ‍the selection of appropriate comparator arms and the‌ management of ancillary immune-modulating treatments.

The next stage of development ⁣must address key pitfalls around comparator arms⁤ and ancillary immune-modulating ​treatments. – ​ Nature Medicine

The success of CAR T-cell therapy for ‌lupus hinges ‍on refining ‌the treatment protocol to maximize efficacy⁤ and minimize potential side effects. Researchers are actively exploring strategies to‌ improve the specificity of‍ the CAR, reduce the risk of cytokine release syndrome⁤ (CRS), and optimize⁣ the conditioning regimen​ prior to cell infusion. Long-term follow-up is also essential to assess the durability of the response ​and ⁣identify any ⁤late-onset complications.

Developing cell‌ therapies for ⁣lupus represents a paradigm shift in how ⁢we approach autoimmune diseases. While still ​in its early stages, this research offers ⁣hope for a future where lupus patients may experience sustained remission and improved⁣ quality of life.

What are your ⁣thoughts on the potential of CAR T-cell therapy to revolutionize⁣ the treatment of⁤ autoimmune diseases ‍like lupus? And, considering the complexities of immune ⁣modulation, what ethical considerations do you think are most critically⁣ important as this field ⁣advances?

The ​Landscape of Lupus⁢ Treatment

Systemic lupus erythematosus has⁢ historically been a challenging ‍disease to treat, with limited​ options offering incomplete relief. Traditional therapies, such as corticosteroids and immunosuppressants, ⁣can manage symptoms but often come with significant side effects. The emergence of targeted therapies, including biologics ⁣like belimumab, has improved outcomes for some patients, but a substantial proportion remain refractory to existing treatments.​ ‍ The ‍development of⁢ CAR T-cell therapy represents a ‌potentially transformative approach, ⁢offering the possibility of resetting the immune system and achieving​ long-term remission. the field‍ of autoimmune disease ​treatment is rapidly evolving, ‌with ongoing​ research exploring novel targets and therapeutic strategies.

Frequently Asked Questions‌ about⁢ CAR T-Cell‍ Therapy​ for ‌Lupus

  • What is CAR T-cell therapy? CAR T-cell therapy is a type of immunotherapy that involves genetically modifying ​a​ patient’s own T⁣ cells to target and destroy specific cells.
  • How does⁤ CAR T-cell therapy work ‍in​ lupus? In lupus, CAR T-cells are engineered to target immune cells that⁢ are‌ contributing to the autoimmune attack on the body’s tissues.
  • Is CAR T-cell therapy a cure for lupus? While early ‌trials are promising,⁣ CAR T-cell therapy is not yet considered⁤ a cure for lupus. ‍Further research is needed to
October 11, 2025 0 comments
0 FacebookTwitterPinterestEmail
Health

Modeling the threat of pfhrp2/3 gene deletions for malaria diagnosis

by Dr. Michael Lee – Health Editor October 11, 2025
written by Dr. Michael Lee – Health Editor

“`html

Malaria Diagnosis Faces Growing Threat from Gene Deletions,⁣ New Modeling Shows

Table of Contents

  • Malaria Diagnosis Faces Growing Threat from Gene Deletions,⁣ New Modeling Shows
    • The Challenge with ⁣pfhrp2/3⁢ Deletions
    • Global Risk Assessment Through Modeling
    • Implications for Malaria control
    • Frequently Asked Questions about ​pfhrp2/3 Deletions and Malaria ‍Diagnosis

May 17, 2024

A⁣ new global risk ⁤assessment reveals a concerning trend: deletions in the plasmodium falciparum ‌ histidine-rich protein 2 and 3 (pfhrp2/3)⁢ genes are⁤ increasingly ⁤jeopardizing the accuracy of rapid diagnostic tests (RDTs)⁣ for ⁣malaria.⁤ Researchers ‌warn that the ‌spread of thes deletions could‌ substantially undermine malaria‌ control⁤ efforts worldwide.

The study, published in Nature Microbiology,⁢ utilizes ​advanced modeling⁢ to predict the⁤ future prevalence of these gene⁤ deletions ‍and their ‍impact on diagnostic capabilities. This research​ highlights the ⁣urgent need for proactive⁣ surveillance and the development of alternative diagnostic strategies.

The Challenge with ⁣pfhrp2/3⁢ Deletions

Rapid diagnostic tests are a ⁣cornerstone of malaria diagnosis, particularly in⁣ resource-limited ​settings. These tests detect the presence of the pfhrp2/3 protein, a​ parasite antigen. However, naturally occurring deletions ​in the genes‍ encoding this protein render the tests ineffective, leading ⁢to false-negative results. ⁤ A false negative⁣ can delay ​treatment and contribute​ to the​ spread of the disease.

The deletions are spreading, and​ the modeling suggests this trend will continue. The study emphasizes that the deletions aren’t uniform; different deletion patterns exist, further complicating diagnostic ⁢development.

Global Risk Assessment Through Modeling

Researchers led ⁢by O.J. Watson and colleagues⁢ conducted a extensive analysis of available data on pfhrp2/3 deletions ​from across the globe. They than employed complex modeling ‍techniques to project the future ⁣risk of‌ these deletions ​impacting RDT performance. The modeling incorporated factors such ⁢as parasite genetic diversity, population movement,⁤ and drug resistance patterns.

Their findings indicate a substantial risk⁣ of widespread diagnostic failure in several key malaria-endemic regions. Specifically, areas in Africa and Southeast Asia are predicted‍ to experience a ⁤meaningful increase in‍ the prevalence of ⁤pfhrp2/3 ‌deletions within the⁤ next‍ decade. The study points to a potential ⁤for diagnostic inaccuracy to rise above ten percent in some areas.

Implications for Malaria control

The increasing prevalence of pfhrp2/3 ‌deletions poses a serious threat to malaria elimination efforts. Accurate diagnosis is crucial for effective⁣ treatment and surveillance. false-negative results ⁢can lead‍ to underreporting of⁤ cases, hindering targeted interventions and perhaps​ fueling outbreaks.

The researchers advocate for enhanced surveillance of pfhrp2/3⁤ deletions to track their spread and inform diagnostic strategies. ⁢Investment in the development of alternative diagnostic tools that do​ not rely on the pfhrp2/3 ⁢protein is​ also critical. ‌These alternatives include tests targeting other ⁤parasite antigens​ or utilizing molecular diagnostic techniques like PCR.

Malaria remains one of the ⁤world’s ‍most devastating⁣ infectious diseases, disproportionately affecting children and ‍pregnant ​women in sub-Saharan Africa. Despite significant progress in recent decades, the fight against malaria is facing new challenges, including the emergence ‍of drug-resistant parasites and‍ the‌ increasing threat of diagnostic inaccuracies. Continued research and ‍innovation‍ are essential​ to⁤ overcome these obstacles and achieve malaria elimination.

Frequently Asked Questions about ​pfhrp2/3 Deletions and Malaria ‍Diagnosis

  • Q: What are pfhrp2/3⁢ deletions?
    A: These are naturally occurring genetic changes in the Plasmodium falciparum parasite that remove parts of ⁢the​ genes responsible for producing the pfhrp2/3⁢ protein, which is detected by ⁣many malaria rapid diagnostic ‌tests.
  • Q: ‍How⁣ do pfhrp2/3 deletions affect ⁢malaria diagnosis?
    A:‌ When⁤ the parasite lacks ⁣the pfhrp2/3‍ protein due​ to these deletions, ‌the rapid diagnostic test will give a false-negative result, meaning it incorrectly indicates that someone does not have malaria.
October 11, 2025 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Search:

Recent Posts

  • Kremlin Praises Trump’s National Security Strategy, Ukraine Peace Talks Stall

    December 7, 2025
  • Yipirinya School Crisis: Principal Guilty, Staff Redundancies Loom

    December 7, 2025
  • Human-AI Collaboration: Optimizing Workflows for Enterprise Success

    December 7, 2025
  • Shakib Al Hasan: Full Series Desire for Bangladesh Farewell

    December 7, 2025
  • Medicare Open Enrollment Deadline: Risks & Benefits of Advantage Plans

    December 7, 2025

Follow Me

Follow Me
  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

@2025 - All Right Reserved.

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: contact@world-today-news.com


Back To Top
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
@2025 - All Right Reserved.

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: contact@world-today-news.com